肝脏疾病中的肝首过代谢 - Suppr

Hepatic first-pass metabolism in liver disease.

作者信息

Blaschke T F, Rubin P C

出版信息

Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32. doi: 10.2165/00003088-197904060-00002.

DOI:10.2165/00003088-197904060-00002

PMID:391462

Abstract

摘要

相似文献

Hepatic first-pass metabolism in liver disease.

Clin Pharmacokinet. 1979 Nov-Dec;4(6):423-32. doi: 10.2165/00003088-197904060-00002.

Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.

Semin Liver Dis. 1983 Nov;3(4):285-97. doi: 10.1055/s-2008-1040781.

Altered drug metabolism and elevated serum bile acids in liver disease: a unified pharmacokinetic explanation.

Gastroenterology. 1980 Jan;78(1):177-9.

Drug administration in hepatic disease.

N Engl J Med. 1983 Dec 29;309(26):1616-22. doi: 10.1056/NEJM198312293092605.

Hepatic clearance measurements and pharmacokinetics.

Pharmacology. 1979;19(3):105-10. doi: 10.1159/000137296.

[Changes in drug kinetics in liver diseases and their importance in rational pharmacotherapy].

Pol Tyg Lek. 1977 Dec 26;32(52):2057-60.

Drug pharmacokinetics in cardiac and hepatic disease.

Annu Rev Pharmacol Toxicol. 1980;20:389-413. doi: 10.1146/annurev.pa.20.040180.002133.

First-pass elimination. Basic concepts and clinical consequences.

Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.

First-pass metabolism.

Practitioner. 1983 Oct;227(1384):1619-27.

Clinical pharmacokinetics.

Annu Rev Pharmacol Toxicol. 1979;19:105-27. doi: 10.1146/annurev.pa.19.040179.000541.

引用本文的文献

To use or not to use: Safety of selected painkillers in patients with chronic liver diseases.

Clin Exp Hepatol. 2025 Jun;11(2):113-120. doi: 10.5114/ceh.2025.151745. Epub 2025 Jun 25.

The assessment and management of pain in cirrhosis.

Curr Hepatol Rep. 2018 Mar;17(1):42-51. doi: 10.1007/s11901-018-0389-7. Epub 2018 Feb 22.

The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.

Hepat Mon. 2014 Oct 11;14(10):e23539. doi: 10.5812/hepatmon.23539. eCollection 2014 Oct.

Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.

Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Drugs. 2012 Aug 20;72(12):1645-69. doi: 10.2165/11635500-000000000-00000.

Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.

Eur J Clin Pharmacol. 2012 Feb;68(2):179-88. doi: 10.1007/s00228-011-1105-5. Epub 2011 Aug 13.

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2.

A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.

Ther Drug Monit. 2008 Jun;30(3):379-89. doi: 10.1097/FTD.0b013e3181778fa3.

Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Pharm World Sci. 1998 Oct;20(5):183-92. doi: 10.1023/a:1008656930082.

Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.

Eur J Clin Pharmacol. 1993;45(3):247-53. doi: 10.1007/BF00315391.

本文引用的文献

The disposition of propranolol. I. Elimination during oral absorption in man.

Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.

Kidney disease and drug metabolism.

Med Clin North Am. 1974 Sep;58(5):1059-62. doi: 10.1016/s0025-7125(16)32101-0.

Route of administration and drug disposition.

Drug Metab Rev. 1974;3(2):185-99. doi: 10.3109/03602537408993742.

Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease.

Am J Med. 1972 Dec;53(6):715-22. doi: 10.1016/0002-9343(72)90188-x.

Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

J Clin Invest. 1974 Apr;53(4):1101-7. doi: 10.1172/JCI107647.

Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.

J Pharmacol Exp Ther. 1975 Dec;195(3):416-23.

Clinical pharmacokinetics of hydrallazine.

Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].

Br J Clin Pharmacol. 1977 Oct;4(5):630P. doi: 10.1111/j.1365-2125.1977.tb00802.x.

Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.

J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501-8. doi: 10.1002/j.1552-4604.1977.tb05643.x.

Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

J Pharmacokinet Biopharm. 1977 Jun;5(3):193-205. doi: 10.1007/BF01065395.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Hepatic first-pass metabolism in liver disease.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献